James S Wainscoat Selected Research

Chromosome 5q Deletion Syndrome

1/2013	Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.
1/2012	Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
1/2012	5q- syndrome.
12/2010	Advances in the 5q- syndrome.
12/2009	Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
7/2007	Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
6/2004	Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James S Wainscoat Research Topics

Disease

7	Chromosome 5q Deletion Syndrome 01/2013 - 06/2004
6	Neoplasms (Cancer) 05/2011 - 01/2006
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2009 - 06/2004
3	Lymphoma (Lymphomas) 05/2011 - 09/2007
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 07/2009 - 09/2007
2	Anemia 01/2013 - 01/2012
2	Thrombocytosis (Thrombocythemia) 01/2012 - 12/2010
2	Refractory Anemia 04/2008 - 07/2006
1	Diamond-Blackfan Anemia (Anemia, Diamond Blackfan) 01/2012
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2012
1	Multiple Myeloma 05/2011
1	Hematologic Neoplasms (Hematological Malignancy) 05/2011
1	B-Cell Lymphoma (Lymphoma, B Cell) 08/2010
1	Sezary Syndrome (Sezary Erythroderma) 08/2010
1	Macrocytic Anemia 01/2010
1	Disease Progression 12/2009
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2009
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 07/2009
1	Autosomal Recessive 3 Severe Congenital Neutropenia 06/2009
1	Uniparental Disomy 07/2008
1	sideroblastic spinocerebellar ataxia Anemia 04/2008
1	Malaria 01/2006
1	Prostatic Neoplasms (Prostate Cancer) 01/2006
1	Polycythemia Vera 07/2003
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 01/2003

Drug/Important Bio-Agent (IBA)

7	MicroRNAs (MicroRNA)IBA 01/2012 - 09/2007
3	Lenalidomide (CC 5013)FDA Link 12/2010 - 07/2007
2	Ribosomal Proteins (Ribosomal Protein)IBA 01/2013 - 01/2012
2	RNA (Ribonucleic Acid)IBA 05/2011 - 07/2009
2	DNA (Deoxyribonucleic Acid)IBA 07/2008 - 01/2006
2	Cell-Free Nucleic AcidsIBA 05/2008 - 01/2006
2	Complementary DNA (cDNA)IBA 06/2004 - 07/2003
1	Amino Acids FDA Link 01/2013
1	Leucine (L-Leucine)FDA Link 01/2013
1	5-hydroxymethylcytosineIBA 01/2012
1	5-Methylcytosine (5 Methylcytosine)IBA 01/2012
1	ribosomal protein S14IBA 01/2010
1	Lymphoid Enhancer-Binding Factor 1IBA 06/2009
1	IronIBA 04/2008
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 04/2008
1	ParaffinIBA 09/2007
1	Proteins (Proteins, Gene)FDA Link 07/2007
1	Heme (Haem)IBA 07/2006
1	InterferonsIBA 07/2006
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2003
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2003

Therapy/Procedure

2	Therapeutics 12/2010 - 07/2007